Poonam Kanta. Regulation of osteoblastic differentiation:a concept note[A]. 上海来溪会务服务有限公司,2018:7.
[2]
Kalil R K, Squire J. Small cell osteosarcoma.WHO classification of tumours of soft tissue and bone[M]. Lyon: IARC Press,2013:291.
[3]
严海林. 骨肉瘤流行病学研究及术前风险评分模型的构建[D].杭州:浙江大学,2017.
[4]
Zahra Najafi. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer[A]. Universal Researchers in Science and Technology,2016:10.
[5]
Isakoff M S, Bielack S S, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to Success[J]. JClinicOncol,2015,33(27):3029-3035.
[6]
Dobreva G, Chahrour M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation[J]. Cell,2006,125(5):971-986.
[7]
Zhang J, Tu Q, Grosschedl R, et al. Roles of SATB2 in osteogenic differentiation and bone regeneration[J]. Tissue engineering Part A,2011,17(13-14):1767-1776.
[8]
Conner J R, Hornick J L. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours[J]. Histopathology,2013,63(1):36-49.
[9]
Ordonez N G. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma[J]. AdvAnatPathol,2014,21(1):63-67.
[10]
李 明, 蔡永萍, 鲁康洋, 等. AT 序列特异性结合蛋白2在骨肉瘤病理诊断中的价值[J]. 中华病理学杂志 2016,45(9):631-635.
[11]
Righi A, Gambarotti M, Longo S, et al. Small cell osteosarcoma: clinicopathologic, immunohistochemical, and molecular analysis of 36 cases[J]. AMJ Surg Pathol,2015,39(5):691-699.
Seong B K, Lau J, Adderley T, et al. SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization[J]. Oncogene,2015,34(27):3582-3592.
[15]
Gaspar N, Hawkins D S, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration[J]. J clinic oncol,2015,33(27):3036-3046.
2020, Vol. 31 
